ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • Search
  • My Favorites
    • View and print all favorites
    • Clear all favorites

Abstract Number: 1649

Parameters by FDG-PET/CT Are Useful for Predicting Spontaneous Regression in MTX Associated Lymphoproliferative Disorder

Tomohiro Kameda1, Shusaku Nakashima1, Hiromi Shimada1, Risa Wakiya1, Mai Fahmy Mansour1, Mikiya Kato1, Koichi Sugihara1, Rina Semba1, Mao Mizusaki1, Norimitsu Kadowaki1 and Hiroaki Dobashi2, 1Kagawa University, Takamatsu, Japan, 2Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Kita-gun, Japan

Meeting: ACR Convergence 2021

Keywords: FDG-PET/CT, methotrexate

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print
Session Information

Date: Tuesday, November 9, 2021

Title: RA – Diagnosis, Manifestations, & Outcomes Poster IV: Outcomes, Trajectory of Disease, & Epidemiology (1645–1673)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: Methotrexate associated lymphoproliferative disorder (MTX-LPD) has various histological types from benign and malignant. Some MTX-LPDs spontaneously regress after discontinuation of MTX, even though they have been diagnosed with malignant lymphoma. However it is difficult to predict spontaneous regression (SR) of MTX-LPD. On the other hand, FDG-PET/CT is used for diagnosis of malignant lymphoma.

We investigate the usefulness of FDG-PET/CT for predictive factor of SR in MTX-LPD.

Methods: We enrolled 18 MTX-RA-LPD patients, which was histopathologically determined to be malignant and performed FDG-PET/CT from 2005 to 2019. We divided these cases into spontaneous regression cases (SR group; 9 cases) and cases that treated with chemotherapy after MTX discontinuation (CTx group; 9 cases), and compared the difference as follow subjects between two groups; biomarker (serum LDH and sIL-2R) at LPD onset, SUVmax to evaluate malignant tumor activity by FDG-PET/CT, metabolic tumor volume (MTV) and total lesion glycolysis (TLG) which refer to metabolically active volume of the tumor segmented FDG-PET/CT. In addition, we analyzed cut off levels, sensitivity and specificity using statistical software JMP.

Results: The level of sIL-2R was significantly lower in SR group. In addition, MTV and TLG by FDG-PET/CT was significantly lower in SR group, although SUVmax is no difference between two groups. Cut off levels of sIL-2R, MTV and TLG were1728 U/ml (sensitivity; 77.8%, specificity; 88.9%) 103.42 ml (sensitivity; 88.9%, specificity; 88.9%) and 361.75 ml (sensitivity; 88.9%, specificity; 88.9%), respectively.

Conclusion: We suggested that serum sIL-2R, MTV and TLG were useful for predict of SR in MTX-LPD.


Disclosures: T. Kameda, None; S. Nakashima, None; H. Shimada, None; R. Wakiya, None; M. Fahmy Mansour, None; M. Kato, None; K. Sugihara, None; R. Semba, None; M. Mizusaki, None; N. Kadowaki, None; H. Dobashi, None.

To cite this abstract in AMA style:

Kameda T, Nakashima S, Shimada H, Wakiya R, Fahmy Mansour M, Kato M, Sugihara K, Semba R, Mizusaki M, Kadowaki N, Dobashi H. Parameters by FDG-PET/CT Are Useful for Predicting Spontaneous Regression in MTX Associated Lymphoproliferative Disorder [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/parameters-by-fdg-pet-ct-are-useful-for-predicting-spontaneous-regression-in-mtx-associated-lymphoproliferative-disorder/. Accessed .
  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/parameters-by-fdg-pet-ct-are-useful-for-predicting-spontaneous-regression-in-mtx-associated-lymphoproliferative-disorder/

Advanced Search

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology